View Financial HealthGNI Group 配当と自社株買い配当金 基準チェック /06GNI Group配当金を支払った記録がありません。主要情報n/a配当利回り-7.7%バイバック利回り総株主利回り-7.7%将来の配当利回り0.6%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Feb 13GNI Group Ltd., Annual General Meeting, Mar 26, 2026GNI Group Ltd., Annual General Meeting, Mar 26, 2026.お知らせ • Jan 23+ 1 more updateGNI Group Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2025GNI Group Ltd. revised consolidated earnings guidance for the fiscal year ending December 31, 2025. For the year, the group now expects Revenue of JPY 26,841 million against previous guidance of JPY 28,733 million, operating loss of JPY 2,725 million against previous guidance of operating profit of JPY 23,217 million, Loss Before Income Taxes of JPY 3,795 million against previous guidance of Profit Before Income Taxes of JPY 22,541 million, Loss attributable to the owners of parent of JPY 3,420 million against previous guidance of profit Attributable to Owners of the Parent of JPY 12,058 million, basic loss per share of JPY 65.18 against previous guidance of basic earnings per share of JPY 240.42. Reasons for Revision: Revenue has been revised primarily due to the pharmaceutical business, as Etorel® (nintedanib), which was launched in 2025, is now expected to fall below the initial budget. Meanwhile, in the pharmaceutical business as a whole, sales of the Company's core product, ETUARY®, continue to perform steadily, and revenue is expected to reach a record high for the 12th consecutive fiscal year since its launch in 2014. In addition, in the Medtech business, following the acquisition of Berkeley Advanced Biomaterials (BAB) in 2017, revenue is expected to reach record highs for the 9th consecutive fiscal year. As a result, consolidated revenue is expected to increase by JPY 3,230 million compared to the previous fiscal year, to JPY 26,841 million. Profit: Deferral of the listing of consolidated subsidiary Cullgen. In the Group's pharmaceutical (Biotech) business, Cullgen Inc. ("Cullgen"), a core subsidiary, has been pursuing a listing on the NASDAQ market in the United States, subject to approval of a reverse merger transaction by the China Securities Regulatory Commission ("CSRC"). The Group had expected the review to be completed and the listing to be achieved within the fiscal year ending December 2025. However, as the approval remains pending at this time, the listing gain of JPY 22,854 million that had been included in the profit forecast for the fiscal year ending December 2025 has been excluded. Furthermore, while the initial forecast assumed Cullgen would transition to an equity-method affiliate following its listing, a change in the timing of the listing has resulted in Cullgen remaining a consolidated subsidiary for the second half of the fiscal year. Accordingly, its full-year estimated operating loss of JPY 3,996 million is now reflected in this revised forecast. Impairment Losses: As a result of impairment tests conducted by an independent third-party firm, the recoverable amounts of goodwill related to MICREN Healthcare Co. Ltd., intangible assets related to Shanghai Genomics Technology Ltd., and fixed assets related to Shanghai Rui Fu International Trade Co. Ltd. were determined to be below their carrying amounts, and an impairment loss totaling JPY 468 million is expected to be recognized. Furthermore, with respect to the transaction review related to Cullgen's listing, the approval process remains ongoing. As disclosed on December 19, 2025, the Group is continuing its efforts toward the early realization of the listing while considering alternative options. If the listing is realized in the future, any listing gain will be recognized in the financial results for the accounting period in which the listing occurs; however, the actual amount of such gain will vary depending on the initial public offering price on the listing date as well as foreign exchange movements.お知らせ • Jan 10GNI Group Ltd. (TSE:2160) acquired ZOO LABO Co., Ltd.GNI Group Ltd. (TSE:2160) acquired ZOO LABO Co., Ltd. on December 29, 2025. A cash consideration will be paid by GNI Group Ltd towards common equity of ZOO LABO Co., Ltd. The funds were sourced from the proceeds raised through the overseas public offering conducted in July 2025. GNI Group Ltd. (TSE:2160) completed the acquisition of ZOO LABO Co., Ltd. on December 29, 2025.お知らせ • Dec 27GNI Group Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026GNI Group Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026お知らせ • Sep 27GNI Group Ltd. to Report Q3, 2025 Results on Nov 14, 2025GNI Group Ltd. announced that they will report Q3, 2025 results on Nov 14, 2025お知らせ • Jul 23GNI Group Ltd. has filed a Follow-on Equity Offering.GNI Group Ltd. has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 4,000,000お知らせ • Jun 27GNI Group Ltd. to Report Q2, 2025 Results on Aug 14, 2025GNI Group Ltd. announced that they will report Q2, 2025 results on Aug 14, 2025お知らせ • Jun 05Gyre Pharmaceuticals Co., Ltd. Announces Launch of Etorel (Nintedanib Esilate Soft Capsules) by Gyre PharmaceuticalsGNI Group Ltd. announced that its core subsidiary, Gyre Pharmaceuticals Co. Ltd., has commenced sales of "Etorel" (Nintedanib Esilate Soft Capsules), as announced on May 8, 2024, in the press release titled "Notice Regarding License Agreement entered into by GNI's Consolidated Subsidiary, Gyre Pharmaceuticals Co. Ltd., as it has secured the only two approved drugs for pulmonary fibrosis worldwide. This achievement has strategic significance in strengthening its position as a global leading company in the treatment of pulmonary fibrosis, continuously expanding its market share, and enhancing its presence in the field of interstitial lung diseases. The market for pulmonary fibrosis is large, with many unmet clinical needs remaining. Nintedanib Esilates Soft Capsules are approved not only for idiopathic pulmonary fibrosis (IPF), but also for systemic sclerosis-associated interstitial lung disease (SSc-ILD) and progressive fibrosing interstitial lung disease (PF-ILD). The impact of this development on the company's performance has already been factored into the current consolidated earnings forecast. The impact of this development on The company's performance has already beenfactored into the current consolidated earnings forecasts. The impact of this development On the company's performance has already be factored into the current consolidated Earn forecast. The impact of this develop on the company's performance has also been factored into the current consolidate earnings forecast. The impact of This development on the company's performance have already been factored into the currently consolidated earnings forecast. The impact the development on the company's performance is already been factored into the existing consolidated earnings forecast.お知らせ • Apr 10GNI Group Ltd. to Report Q1, 2025 Results on May 15, 2025GNI Group Ltd. announced that they will report Q1, 2025 results on May 15, 2025お知らせ • Feb 18GNI Group Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2025GNI Group Ltd. provided consolidated earnings guidance for the full year ending December 31, 2025. For the year, the company expects revenue of JPY 28,733 million, operating profit of JPY 23,217 million, profit for the year of JPY 15,868 million and basic earnings per share of JPY 240.42.お知らせ • Feb 17GNI Group Ltd., Annual General Meeting, Mar 27, 2025GNI Group Ltd., Annual General Meeting, Mar 27, 2025.お知らせ • Jan 03GNI Group Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025GNI Group Ltd. announced that they will report fiscal year 2024 results on Feb 14, 2025決済の安定と成長配当データの取得安定した配当: GNII.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: GNII.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場GNI Group 配当利回り対市場GNII.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (GNII.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.4%アナリスト予想 (GNII.F) (最長3年)0.6%注目すべき配当: GNII.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: GNII.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: GNII.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: GNII.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/03/15 02:27終値2025/12/16 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋GNI Group Ltd. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Stephen BarkerJefferies LLCYuriko IshidaMizuho Securities Co., Ltd.null nullStorm Research Limited
お知らせ • Feb 13GNI Group Ltd., Annual General Meeting, Mar 26, 2026GNI Group Ltd., Annual General Meeting, Mar 26, 2026.
お知らせ • Jan 23+ 1 more updateGNI Group Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2025GNI Group Ltd. revised consolidated earnings guidance for the fiscal year ending December 31, 2025. For the year, the group now expects Revenue of JPY 26,841 million against previous guidance of JPY 28,733 million, operating loss of JPY 2,725 million against previous guidance of operating profit of JPY 23,217 million, Loss Before Income Taxes of JPY 3,795 million against previous guidance of Profit Before Income Taxes of JPY 22,541 million, Loss attributable to the owners of parent of JPY 3,420 million against previous guidance of profit Attributable to Owners of the Parent of JPY 12,058 million, basic loss per share of JPY 65.18 against previous guidance of basic earnings per share of JPY 240.42. Reasons for Revision: Revenue has been revised primarily due to the pharmaceutical business, as Etorel® (nintedanib), which was launched in 2025, is now expected to fall below the initial budget. Meanwhile, in the pharmaceutical business as a whole, sales of the Company's core product, ETUARY®, continue to perform steadily, and revenue is expected to reach a record high for the 12th consecutive fiscal year since its launch in 2014. In addition, in the Medtech business, following the acquisition of Berkeley Advanced Biomaterials (BAB) in 2017, revenue is expected to reach record highs for the 9th consecutive fiscal year. As a result, consolidated revenue is expected to increase by JPY 3,230 million compared to the previous fiscal year, to JPY 26,841 million. Profit: Deferral of the listing of consolidated subsidiary Cullgen. In the Group's pharmaceutical (Biotech) business, Cullgen Inc. ("Cullgen"), a core subsidiary, has been pursuing a listing on the NASDAQ market in the United States, subject to approval of a reverse merger transaction by the China Securities Regulatory Commission ("CSRC"). The Group had expected the review to be completed and the listing to be achieved within the fiscal year ending December 2025. However, as the approval remains pending at this time, the listing gain of JPY 22,854 million that had been included in the profit forecast for the fiscal year ending December 2025 has been excluded. Furthermore, while the initial forecast assumed Cullgen would transition to an equity-method affiliate following its listing, a change in the timing of the listing has resulted in Cullgen remaining a consolidated subsidiary for the second half of the fiscal year. Accordingly, its full-year estimated operating loss of JPY 3,996 million is now reflected in this revised forecast. Impairment Losses: As a result of impairment tests conducted by an independent third-party firm, the recoverable amounts of goodwill related to MICREN Healthcare Co. Ltd., intangible assets related to Shanghai Genomics Technology Ltd., and fixed assets related to Shanghai Rui Fu International Trade Co. Ltd. were determined to be below their carrying amounts, and an impairment loss totaling JPY 468 million is expected to be recognized. Furthermore, with respect to the transaction review related to Cullgen's listing, the approval process remains ongoing. As disclosed on December 19, 2025, the Group is continuing its efforts toward the early realization of the listing while considering alternative options. If the listing is realized in the future, any listing gain will be recognized in the financial results for the accounting period in which the listing occurs; however, the actual amount of such gain will vary depending on the initial public offering price on the listing date as well as foreign exchange movements.
お知らせ • Jan 10GNI Group Ltd. (TSE:2160) acquired ZOO LABO Co., Ltd.GNI Group Ltd. (TSE:2160) acquired ZOO LABO Co., Ltd. on December 29, 2025. A cash consideration will be paid by GNI Group Ltd towards common equity of ZOO LABO Co., Ltd. The funds were sourced from the proceeds raised through the overseas public offering conducted in July 2025. GNI Group Ltd. (TSE:2160) completed the acquisition of ZOO LABO Co., Ltd. on December 29, 2025.
お知らせ • Dec 27GNI Group Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026GNI Group Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026
お知らせ • Sep 27GNI Group Ltd. to Report Q3, 2025 Results on Nov 14, 2025GNI Group Ltd. announced that they will report Q3, 2025 results on Nov 14, 2025
お知らせ • Jul 23GNI Group Ltd. has filed a Follow-on Equity Offering.GNI Group Ltd. has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 4,000,000
お知らせ • Jun 27GNI Group Ltd. to Report Q2, 2025 Results on Aug 14, 2025GNI Group Ltd. announced that they will report Q2, 2025 results on Aug 14, 2025
お知らせ • Jun 05Gyre Pharmaceuticals Co., Ltd. Announces Launch of Etorel (Nintedanib Esilate Soft Capsules) by Gyre PharmaceuticalsGNI Group Ltd. announced that its core subsidiary, Gyre Pharmaceuticals Co. Ltd., has commenced sales of "Etorel" (Nintedanib Esilate Soft Capsules), as announced on May 8, 2024, in the press release titled "Notice Regarding License Agreement entered into by GNI's Consolidated Subsidiary, Gyre Pharmaceuticals Co. Ltd., as it has secured the only two approved drugs for pulmonary fibrosis worldwide. This achievement has strategic significance in strengthening its position as a global leading company in the treatment of pulmonary fibrosis, continuously expanding its market share, and enhancing its presence in the field of interstitial lung diseases. The market for pulmonary fibrosis is large, with many unmet clinical needs remaining. Nintedanib Esilates Soft Capsules are approved not only for idiopathic pulmonary fibrosis (IPF), but also for systemic sclerosis-associated interstitial lung disease (SSc-ILD) and progressive fibrosing interstitial lung disease (PF-ILD). The impact of this development on the company's performance has already been factored into the current consolidated earnings forecast. The impact of this development on The company's performance has already beenfactored into the current consolidated earnings forecasts. The impact of this development On the company's performance has already be factored into the current consolidated Earn forecast. The impact of this develop on the company's performance has also been factored into the current consolidate earnings forecast. The impact of This development on the company's performance have already been factored into the currently consolidated earnings forecast. The impact the development on the company's performance is already been factored into the existing consolidated earnings forecast.
お知らせ • Apr 10GNI Group Ltd. to Report Q1, 2025 Results on May 15, 2025GNI Group Ltd. announced that they will report Q1, 2025 results on May 15, 2025
お知らせ • Feb 18GNI Group Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2025GNI Group Ltd. provided consolidated earnings guidance for the full year ending December 31, 2025. For the year, the company expects revenue of JPY 28,733 million, operating profit of JPY 23,217 million, profit for the year of JPY 15,868 million and basic earnings per share of JPY 240.42.
お知らせ • Feb 17GNI Group Ltd., Annual General Meeting, Mar 27, 2025GNI Group Ltd., Annual General Meeting, Mar 27, 2025.
お知らせ • Jan 03GNI Group Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025GNI Group Ltd. announced that they will report fiscal year 2024 results on Feb 14, 2025